《大行報告》麥格理降財險(02328.HK)評級至「中性」 目標價上調至8元
麥格理發表研究報告,指中國財險(02328.HK)至今在減少車保改革對毛利衝擊上有所建樹,股份亦獲得重評,惟該行預期未來數季最差情況尚未來到,下調今明兩年每股盈測5%及7%,將目標價升11%至8元,但投資評級降至「中性」。
報告稱,現估值不高,但不認為近期反彈可以持續,直至有更多證據顯示中期承保毛利率可見度上升。反之市場對短期毛利率預期或過於樂觀,該行認為有下行風險。
麥格理稱,財險首季綜合成本率(CoR)僅輕微升至94.6%屬健康,但在短期及中期而言料不可持續。該行分析指其毛利率壓力今年趨升,集中於首三季,並料第四季初期見頂,並料首季CoR未反映該趨勢。(da/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.